Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure

J Eur Acad Dermatol Venereol. 2017 May;31(5):e253-e254. doi: 10.1111/jdv.14010. Epub 2016 Oct 28.

Authors

M Arenbergerova¹, I Mrazova², J Horazdovsky³, E Sticova⁴, A Fialova¹, P Arenberger¹

Affiliations

¹ Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
² Department of Oncology and Radiotherapy, Ceske Budejovice Hospital, Ceske Budejovice, Czech Republic.
³ Department of Dermatovenereology, Ceske Budejovice Hospital, Ceske Budejovice, Czech Republic.
⁴ Department of Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.

PMID: 27739125
DOI: 10.1111/jdv.14010

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Biopsy
Female
Humans
Melanoma / drug therapy
Melanoma, Cutaneous Malignant
Middle Aged
Nivolumab / pharmacology*
Scalp
Skin / pathology
Skin Neoplasms / drug therapy
Stevens-Johnson Syndrome / diagnosis
Stevens-Johnson Syndrome / etiology*
Treatment Failure
Vemurafenib / adverse effects*
Vemurafenib / therapeutic use

Substances

Antineoplastic Agents
Vemurafenib
Nivolumab